New research suggests that treating patients with non-steroidal anti-inflammatory drugs (NSAIDs) may mobilise more stem cells out of the bone marrow for peripheral blood stem cell collection – in animal studies by as much as four to six times.
Peter Adamson, MD, head of the Children’s Oncology Group, expresses his fears regarding what the sequestration will mean for future funding of paediatric clinical trials by the National Cancer Institute.
‘The Cancer Letter’ carries the full interview in Vol. 39, Issue 11, and a recording is also available to download.
In a stark reminder that more effective and less toxic treatments are desperately required, a report in the Journal of the National Cancer Institute, investigating the risk of second malignancies among adult survivors of childhood cancer, finds increased risk of renal carcinoma. In particular the highest risk was observed amongst neuroblastoma survivors.
Previous analysis of the same patient cohort found that nearly 10% of childhood cancer survivors went on to develop a secondary malignancy at up to 30 years after initial diagnosis, with Hodgkin lymphoma and Ewing sarcoma carrying the greatest risk.
This interesting article discusses T-Cell immunotherapy, an area of growing research in relation to neuroblastoma treatment. In particular neuroblastoma cells express surface antigens that are also found on certain adult cancers that are the subject of ongoing clinical studies.
Functional Characteristics of Antitumor T Cells Change With Increasing Time After Therapeutic Transfer
PHILADELPHIA — Scientists have characterized how the functionality of genetically engineered T cells administered therapeutically to patients with melanoma changed over time. The data, which are published in Cancer Discovery, a journal of the American Association for Cancer Research, highlight the need for new strategies to sustain antitumor T cell functionality to increase the effectiveness of this immunotherapeutic approach.
Early immunisation with dendritic cells after allogeneic bone marrow transplantation elicits graft vs tumour reactivity
Research study into the effect of early immunisation of neuroblastoma implanted mice with dendritic cells following allogeneic stem cell transplantation.
In a new study published by STEM CELLS Translational Medicine, scientists report on a way to produce natural cancer-killing cells in the lab in a quantity that could one day make them viable for treating patients.
Nanoparticles encapsulated inside liposomes could hold promise of more effective and less toxic delivery of drugs to treat cancer.